Powering the AI Economy: New to The Street Show #776 Premieres Tonight on Bloomberg Television

New to The Street’s sponsored Show #776 premieres on Bloomberg Television at 6:30 p.m. ET on October 17, 2026, featuring American Fusion, solid-state battery company HPB, T-REX Acquisition Corp. and AI restaurant-supply platform SyncMeOn. T-REX described a planned Georgia data-center acquisition and said it had engaged an investment bank to raise up to $25 million; SyncMeOn lists more than 3,000 products in New York and has begun expanding into Connecticut. The article is promotional programming coverage and reports no market reaction; a featured BioVie commercial notes Phase 2 long-COVID results favored placebo on 21 of 22 overall endpoints, requiring Phase 3 confirmation.

Analysis

This is paid distribution, not independent validation. The investable signal is chiefly a potential attention/liquidity event in small, speculative names—not evidence of near-term earnings. Avoid treating a Bloomberg slot, subscriber reach, or executive claims as customer traction; verify filings, counterparties, cash runway and executable contracts.

Over 1–3 months, American Fusion’s thesis only advances with independently verifiable engineering milestones and a binding power-purchase agreement; data-center power demand does not establish that its fusion platform is commercially ready. HPB’s licensing angle faces the same gap between test results and repeatable, qualified production. Watch for signed licensing terms, manufacturing yields and customer qualification, not further interviews. For T-REX, the financing and acquisition create dilution and closing risk; bitcoin exposure also leaves equity holders bearing power-cost and capital-intensity risk. SyncMeOn’s potential procurement savings are not yet proof of durable marketplace economics: supplier participation, order frequency and retention matter more than product listings.

The contrarian point: the AI-power narrative may lift attention across all four businesses, but it can obscure radically different commercialization timelines. Fusion and solid-state batteries are long-dated options; mining is near-term commodity/capital exposure; restaurant software is an adoption and unit-economics test. Separately, BioVie’s advertised long-COVID results—where placebo favored on nearly all reported endpoints—are a material efficacy warning, not a bullish catalyst absent a convincing explanation and confirmatory evidence. No broad thematic trade is justified from this release alone.

Key Decisions for Investors

• Do not chase event-driven moves around the broadcast; stay flat absent a filing-backed catalyst and adequate liquidity. Treat any sharp volume/price spike as a potential fade only after checking borrow availability, spreads and promotional trading risk.
• Put American Fusion and HPB on a milestone watchlist, not a commercial-revenue thesis: require binding customer/licensing agreements plus independently verifiable deployment or production evidence. Reassess if those milestones slip or claimed performance cannot be reproduced.
• For T-REX, monitor transaction closing conditions, financing terms, dilution and post-close power economics before taking exposure; a failed raise or acquisition delay would falsify the near-term expansion case. Bitcoin price strength alone does not resolve these risks.
• For SyncMeOn, seek evidence of repeat ordering, supplier depth, customer retention and realized savings before underwriting marketplace scale; the article provides no basis for a public-equity position. Treat BioVie’s reported endpoint pattern as a caution flag pending confirmation and explanation.